VALBIOTIS

INVESTORS PRESENTATION

July 2020

01.

02.

03.

04.

05.

06.

2

VALBIOTIS / Corporate

TOTUM-63, to reduce the risk of type 2 diabetes

TOTUM-070, to reduce hypercholesterolemia

TOTUM-854, to reduce blood pressure

TOTUM-448, to reduce non-alcoholic hepatic steatosis (NAFL)

FINANCIAL INFORMATION

© NON CONFIDENTIAL

A R&D company, committed

3

to scientific innovation,

for preventing and combating

metabolic diseases

Active substances from plants and based on science, to address unmet medical needs

  • An innovative approach,
    enabled by a specific expertise of plants
  • A high level of evidence, with clinical studies and health claims
  • A pipeline of innovative active substances in Nutrition Healthcare, engineered in our R&D centers
  • 4 patent families registered on 5 continents

© NON CONFIDENTIAL

4

Nutrition Healthcare:

a portfolio of active substances, in clinical stages

Phase II

Phase II/III

Study launch

Results

TOTUM-63 / Prediabetes

Mid-2020

S1 2022

TOTUM-070 / Hypercholesterolemia

Q3 2020

Q4 2021

TOTUM-854 / Arterial hypertension

Q4 2020

Q1 2022

TOTUM-448 / Fatty Liver

S2 2021

-

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Valbiotis SA published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 05:49:06 UTC